Study	Involves genomics	Genomics inclusion summary	Call context	Gene	Alteration Type	Position	Has additional requirement	Gene(additional)	Alteration Type(additional)	Position(additional)	Exclusions (not consistently filled in)	Intervention	Overall status
NCT00107536	yes	any EGFR, ERBB2	somatic	EGFR,ERBB2	mutation,insertion,deletion,fusion	any	no					lapatinib ditosylate	Completed
						any							
NCT00553332	yes	mut in RAS/RAF/MEK/ERK pathway; RAS muts (NRAS,KRAS,HRAS) or any BRAF	somatic	NRAS,KRAS,HRAS	mutation,insertion,deletion,fusion	any	no					selumetinib (AZD6244)	Completed
NCT00553332	yes	mut in RAS/RAF/MEK/ERK pathway; RAS muts (NRAS,KRAS,HRAS) or any BRAF	somatic	BRAF	mutation,insertion,deletion,fusion	any	no					selumetinib (AZD6244)	Completed
NCT00779454	yes	KRAS WT arm	somatic	KRAS	none		no					Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine	Completed
NCT00779454	yes	KRAS "mutated"	somatic	KRAS	mutation,insertion,deletion,fusion	any	no					Gemcitabine, Oxaliplatin, Capecitabine	Completed
NCT00779454	:duplicate:												
NCT00779454	:duplicate:												
NCT01320254	yes	KRAS WT	somatic	KRAS	none		no					Cisplatin and Gemcitabine with or without Panitumumab	Completed
NCT01643499	yes	(Yes, this study mentioned CHOL) UGT1A1 alterations	somatic	UGT1A1	mutation,insertion,deletion,fusion	any	no					irinotecan in FOLFIRINOX	Completed
NCT01752920	yes	FGFR abers, includng iCCA with FGFR2 gene fusion	somatic	FGFR1,FGFR2,FGFR3,FGFR4	mutation,insertion,deletion,fusion	any	no					derazantinib	Completed
NCT01752920	:duplicate:												
NCT02052778	yes	Phase 1:   1+ FGF/FGFR aberr..  Can include FGFR2 fusions or other FGFR2 aberr.  -OR- FGFR3 fusion or activating muts; any FGFR fusions, mut;   	somatic	FGFR1,FGFR2,FGFR3,FGFR4	mutation,insertion,deletion,fusion	any	no					futibatinib	Active, not recruiting
NCT02052778	yes	Phase 2: FGFR2 rearr. or fusion	somatic	FGFR2	insertion,deletion,fusion	any	no					futibatinib	Active, not recruiting
NCT02052778	:duplicate:												
NCT02073994	yes	IDH1 mut.	somatic	IDH1	mutation,insertion,deletion	any	no					AG-120	Active, not recruiting
NCT02073994	:duplicate:												
NCT02150967	yes	cohort 1:  FGFR2 fusions & rearrangements  and other FGFR nonfusion alterations.  Cohort 2: FGFR alts other than FGFR2 gene fusions or rearrangements	somatic	FGFR1,FGFR2,FGFR3,FGFR4	mutation,insertion,deletion,fusion	any	no					infigratinib	Completed
NCT02150967	:duplicate:												
NCT02273739	yes	IDH2 mut	somatic	IDH2	mutation,insertion,deletion	any	no					enasidenib	Completed
NCT02273739	:duplicate:												
NCT02381886	yes	IDH1R132 muts.	somatic	IDH1	mutation	R132:any:	no					IDH305	Active, not recruiting
NCT02393248	yes	FGF or FGFR  muts	somatic	FGFR1,FGFR2,FGFR3,FGFR4	mutation,insertion,deletion	any	no					Pemigatinib mono & combo therapies	Completed
NCT02428855	yes	IDH1 or IDH2 mut	somatic	IDH1,IDH2	mutation,insertion,deletion	any	no					Dasatinib	Completed
NCT02428855	:duplicate:												
NCT02496741	yes	IDH1 or IDH2 mut.	somatic	IDH1,IDH2	mutation,insertion,deletion	any	no					Metformin + chloroquine	Completed
NCT02496741	:duplicate:												
NCT02496741	:duplicate:												
NCT02520141	yes	there is a 10-patient expanded cohort looking for DNA repair aberr. or FGFR genetic aberr.	somatic	:dna_repair:	mutation,insertion,deletion,fusion	any	no					Ramucirumab	Completed
NCT02520141	yes	there is a 10-patient expanded cohort looking for DNA repair aberr. or FGFR genetic aberr.	somatic	FGFR1,FGFR2,FGFR3,FGFR4	mutation,insertion,deletion,fusion	any	no					Ramucirumab	Completed
NCT02568267	yes	NTRK1/2/3, ROS1, or ALK rearr (summary says fusion).	somatic	NTRK1,NTRK2,NTRK3,ROS1,ALK	fusion	any	no					entrectinib	Recruiting
NCT02568267	:duplicate:												
NCT02609958	yes	implied ErbB family mutations; EGFR expr, HER2 overexp., . HER4	somatic	ERBB2,ERBB3,ERBB4,EGFR	mutation,insertion,deletion	any	no					Varlitinib	Completed
NCT02609958	:duplicate:												
NCT02699606	yes	FGFR translocations; FGFR mutations; FGFR pathway activation or other potential target/pathway inhibited by erdafitinib  [FGFR1-4]	somatic	FGFR1,FGFR2,FGFR3,FGFR4	mutation,insertion,deletion,fusion	any	no					Erdafitinib	Active, not recruiting
NCT02784795	yes	any alterations related to NOTCH pathway [is NOTCH1-4 good enough?]	somatic	NOTCH1,NOTCH2,NOTCH3,NOTCH4	mutation,fusion	any	no					LY3039478 combo therapy	Completed
NCT02924376	yes	FGFR2 transloc. with a documented fusion partner  -OR- other FGF/FGFR alterations -OR-   FGF/FGFR  WT	somatic	FGFR1,FGFR2,FGFR3,FGFR4	mutation,insertion,deletion,fusion	any	no					Pemigatinib	Completed
NCT02924376	yes	FGFR2 transloc. with a documented fusion partner  -OR- other FGF/FGFR alterations -OR-   FGF/FGFR  WT	somatic	FGFR1,FGFR2,FGFR3,FGFR4	none		no					Pemigatinib	Completed
NCT02924376	:duplicate:												
NCT02989857	yes	IDH1-mutated (R132C/L/G/H/S)	somatic	IDH1	mutation	R132C,R132L,R132G,R132H,R132S	no					AG-120	Completed
NCT02989857	:duplicate:												
NCT03207347	yes	          -  Known DNA damage repair mutation including any one of the following: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1,    IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52,   RAD54, RPA1, SLX4, WRN, or XRCC. Only CLIA certified next generation sequencing (NGS)  assays are acceptable. Variants of unknown significance (VUS) will be allowed to  enroll on study. (Cohort B only)	somatic	:dna_repair:	mutation,insertion,deletion,fusion	any	no					Niraparib	Active, not recruiting
NCT03207347	yes		germline	:dna_repair:	mutation,insertion,deletion,fusion	any	no					Niraparib	Active, not recruiting
NCT03207347	:duplicate:												
NCT03207347	:duplicate:												
NCT03212274	yes	 include IDH1: R132V, R132G, R132S	somatic	IDH1	mutation	R132V, R132G, R132S, R132L, R132C, R132H	no					olaparib	Recruiting
NCT03212274	yes	             R132L, R132C and R132H; IDH2: R140W, R140L, R140Q, R172W, R172G, R172S, R172M, R172K	somatic	IDH2	mutation	R140W, R140L, R140Q, R172W, R172G, R172S, R172M, R172K	no						Recruiting
NCT03212274	:duplicate:												
NCT03230318	yes	FGFR2 fusion (also FGFR2 mut/amp)	somatic	FGFR2	mutation,insertion,deletion,fusion	any	no					Derazantinib	Active, not recruiting
NCT03230318	:duplicate:												
NCT03345303	yes	PTEN mut / del	somatic	PTEN	mutation,insertion,deletion	any	no					Bortezomib	Recruiting
NCT03656536	yes	FGFR2 rearrangment	somatic	FGFR2	insertion,deletion,fusion	any	no					Pemigatinib or Gemcitabine + Cisplatin	Recruiting
NCT03656536	:duplicate:												
NCT03684811	yes	IDH1-R132 gene-mutated disease	somatic	IDH1	mutation	R132:any:	no					FT-2102 mono and combo therapies	Completed
NCT03773302	yes	activating FGFR2 fusion/rearr. 	somatic	FGFR2	insertion,deletion,fusion	any	no					Gemcitabine + Cisplatin and/or Infigratinib (BGJ398) 	Recruiting
NCT03773302	:duplicate:												
NCT03878095	yes	IDH1 or IDH2 mut	somatic	IDH1,IDH2	mutation,insertion,deletion,fusion	any	no					olaparib and ceralasertib (AZD6738)	Recruiting
NCT03878095	:duplicate:												
NCT03991832	yes	IDH1 or IDH2 mut	somatic	IDH1,IDH2	mutation,insertion,deletion,fusion	any	no					olaparib + durvalumab	Recruiting
NCT03991832	:duplicate:												
NCT03991832	:duplicate:												
NCT04034238	yes	dMMR / MSI-high	somatic	:mm_repair:	mutation,insertion,deletion,fusion	any	no					LMB-100 + tofacitinib	Active, not recruiting
NCT04088188	yes	IDH1  R132C/L/G/H/S 	somatic	IDH1	mutation	R132C, R132L, R132G, R132H, R132S 	no					ivosidenib, cisplatin, gemcitabine	Recruiting
NCT04088188	yes	FGFR2 alteration   [pem. was approved for fusion or other rearr.]	somatic	FGFR2	mutation,insertion,deletion,fusion	any	no					pemigatinib, cisplatin, gemcitabine	Recruiting
NCT04093362	yes	FGFR2 rearrangements (assume fusions)	somatic	FGFR2	insertion,deletion,fusion	any	no					futibatinib	Recruiting
NCT04093362	:duplicate:												
NCT04093362	:duplicate:												
NCT04149691	yes	alteration within FGFR1/2/or 3 [alteration is genetic mutation]	somatic	FGFR1,FGFR2,FGFR3	mutation,insertion,deletion,fusion	any	no					CPL304110	Recruiting
NCT04149691	:duplicate:												
NCT04190628	yes	any BRAF V600 mutation	somatic	BRAF	mutation	V600:any:	no					ABM-1310 w/or w/o Cobimetinib	Recruiting
NCT04190628	:duplicate:												
NCT04190628	:duplicate:												
NCT04233567	yes	FGFR1-3 fusions/transloc. or activating mutations (Cohort  1 &2 ); alterations (such as point mut, ins/del, or amp) in any FGFR gene (Chort 3)	somatic	FGFR1,FGFR2,FGFR3	mutation,insertion,deletion,fusion	any	no					Infigratinib	Recruiting
NCT04233567	:duplicate:												
NCT04233567	:duplicate:												
NCT04238715	yes	FGFR2 fusion (only)	somatic	FGFR2	fusion	any	no					E7090	Recruiting
NCT04238715	:duplicate:												
NCT04256980	yes	FGFR2 rearr.	somatic	FGFR2	insertion,deletion,fusion	any	no					Pemigatinib	Active, not recruiting
NCT04256980	:duplicate:												
NCT04353375	yes	FGFR2 fusion	somatic	FGFR2	fusion	any	no					HMPL-453 tartrate	Not yet recruiting
NCT04353375	:duplicate:												
NCT04353375	:duplicate:												
NCT04383210	yes	NRG1 fusion 	somatic	NRG1	fusion	any	no					Seribantumab	Recruiting
NCT04383210	:duplicate:												
NCT04383210	:duplicate:												
NCT04521686	yes	IDH1 R132 mut, IDH2 R140, or IDH2 R172 mut.	somatic	IDH1	mutation	R132:any:	no					LY3410738 mono or combo therapy	Recruiting
NCT04521686	yes	IDH1 R132 mut, IDH2 R140, or IDH2 R172 mut.	somatic	IDH2	mutation	R140:any:,R172:any:	no					LY3410738 mono or combo therapy	Recruiting
NCT04521686	:duplicate:												
NCT04526106	yes	FGFR2 fusion, mut, or amp. (blood or tumor).  Additional FGFR2 alterations may be considered	somatic	FGFR2	mutation,insertion,deletion,fusion	any	no					RLY-4008	Recruiting
NCT04565275	yes	FGFR gene alterations	somatic	FGFR1,FGFR2,FGFR3,FGFR4	mutation,insertion,deletion,fusion	any	no					ICP-192	Recruiting
NCT04565275	:duplicate:												
NCT04565275	:duplicate:												
NCT04566133	yes	KRAS mut of clinical significance	somatic	KRAS	mutation,insertion,deletion,fusion	any	no					Trametinib + hydroxychloroquine	Recruiting
NCT04566133	:duplicate:												
NCT04566133	:duplicate:												
NCT04762602	yes	IDH1/2 mutation	somatic	IDH1,IDH2	mutation,insertion,deletion,fusion	any	no					HMPL-306	Recruiting
NCT04762602	:duplicate:												
NCT04762602	:duplicate:												
NCT04764084	yes	HER2 negative.  Carry pathogenic or suspected pathogenic germline or somatic HRR(homologous recombination repair) gene mutations, HRR genes include BRCA1, BRCA2, ATM, ATR, BAP1, BRIP1, CHEK2, FANCA, PALB2 and RAD51 mutations in other HRR genes should be evaluated by researchers and the pathogenicity  should be supported by published literature or clinical studies. Description says gBRCA or sBRCA mutations, or HRR gene muts.	somatic	:hr_repair:	mutation,insertion,deletion,fusion	any	no				ERBB2/mutation,fusion/any	Niraparib + Anlotinib	Not yet recruiting
NCT04764084	yes		germline	:hr_repair:	mutation,insertion,deletion,fusion	any	no				ERBB2/mutation,fusion/any	Niraparib + Anlotinib	Not yet recruiting
NCT04764084	:duplicate:												
NCT04794699	yes	homozygous loss of MTAP or MTAP deletion. [likely not germline since homozyg. Del of CDK2NA locus often results in co-deletion of MTAP in GBM, for example]	somatic	MTAP	deletion	any						IDE397 (MAT2A inhibitor)	Recruiting
NCT04853017	yes	KRAS/NRAS mutated (G12D or G12R)	somatic	KRAS,NRAS	mutation	G12D,G12R	no					ELI-002-2P immunotherapy	Recruiting
NCT04853017	:duplicate:												
NCT04919642	yes	FGFR2 fusions (Cohort A1, A2);  other FGFR alterations incl. FGFR2 mut and FGFR1/3 alterations, incl. fusions  (cohort B);  FGFR WT (cohort C)	somatic	FGFR1,FGFR2,FGFR3	mutation,insertion,deletion,fusion	any	no					TT-00420	Recruiting
NCT04919642	yes	FGFR2 fusions (Cohort A1, A2);  other FGFR alterations incl. FGFR2 mut and FGFR1/3 alterations, incl. fusions  (cohort B);  FGFR WT (cohort C)	somatic	FGFR1,FGFR2,FGFR3	none		no					TT-00420	Recruiting
NCT04919642	:duplicate:												
NCT04919642	:duplicate:												
NCT05174650	yes	FGFR2 fusion/rearrangemnt	somatic	FGFR2	insertion,deletion,fusion	any	no					Atezolizumab + Derazantinib	Recruiting
NCT05174650	:duplicate:												
NCT05194735	:skip:	targetable oncogene alterations (eg BRAF, FGFR2, HER2)  [on web, I'm seeing IDH1/2, HER2, BRAF, FGFR1-3, plus whatever mentioned above]. Skipping on account of first looking for specified targets	somatic									treated autologous T-cells with or without Aldesleukin (IL-2)	Recruiting
NCT05194735	:duplicate:												
NCT05242822	yes	FGFR2 and/or FGFR3 gene alt. 	somatic	FGFR2,FGFR3	mutation,insertion,deletion,fusion	any	no					KIN-3248	Recruiting
NCT05242822	:duplicate:												
NCT05242822	:duplicate:												
NCT01308840	yes	combined KRAS / BRAF WT	somatic	KRAS	none		yes	BRAF	none			Gemcitabine + Oxaliplatin + Panitumumab	Completed
NCT01524978	yes	BRAF V600	somatic	BRAF	mutation	V600:any:	no					vemurafenib	Completed
NCT01524978	:duplicate:												
NCT01773655	yes	tissue analysis of germline and somatic BAP1  (BRCA1 associated protein) mutation or loss of expression	somatic	BAP1	mutation,insertion,deletion,fusion	any	no					no therapy/evaluative	Completed
NCT01773655	yes		germline	BAP1	mutation,insertion,deletion,fusion	any	no					no therapy/evaluative	Completed
NCT01773655	:duplicate:												
NCT01773655	:duplicate:												
NCT01773655	:duplicate:												
NCT02034981	yes	Alteration on ALK, MET, RON, or ROS1 depending on cohort (for cholangio., they want ROS1 translocations)	somatic	ROS1	insertion,deletion,fusion	any	no					Crizotinib	Active, not recruiting
NCT02034981	:duplicate:												
NCT02034981	:duplicate:												
NCT02304809	yes	BRAF V600-mut. 	somatic	BRAF	mutation	V600:any:	no				excl: BRAF V600-mut melanoma or CRC	Vemurafenib	Active, not recruiting
NCT02304809	:duplicate:												
NCT02304809	:duplicate:												
NCT02564900	yes	HER2 expression or mutation (part 2d, not BRCA or GI/GEJ adeno)	somatic	ERBB2	mutation,insertion,deletion,fusion	any	no					DS-8201a	Active, not recruiting
NCT02576444	yes	in CHOL: IDH 1/2 tumors; tumor with mut. in homologous DNA repair genes	somatic	IDH1,IDH2	mutation,insertion,deletion,fusion	any	no					olaparib	Active, not recruiting
NCT02576444	yes		somatic	:hr_repair:	mutation,insertion,deletion,fusion	any	no					olaparib	Active, not recruiting
NCT02576444	yes		germline	:hr_repair:	mutation,insertion,deletion,fusion	any	no					olaparib	Active, not recruiting
NCT02576444	yes	Group 2; include other aberrations leading to dysregulation of PI3K/AKT pathway	somatic	PTEN,PIK3CA,AKT,ARID1A	mutation,insertion,deletion,fusion	any	no					AZD5363 + olaparib	Active, not recruiting
NCT02576444	yes	Group 3: KRAS and/or TP53 where TP53 muts are on eligibility list	somatic	TP53,KRAS	mutation,insertion,deletion,fusion	any	no					AZD1775 + olaparib	Active, not recruiting
NCT02576444	:skip:	Group 4: [likely implicitly non-CHOL]  tumors with muts in homol. DNA repair genes including ATM, CHK2, APOBEC [not a hugo symbol], MRE11 complex. Also MRN (MRE11/NBS1 [=NBN]/RAD50), CDKN2A/B											
NCT02648724	:skip:	KRAS WT with MET amp.	somatic	KRAS	none		no					Sym015	Completed
NCT02648724	:duplicate:												
NCT02746081	yes	IDH1-R132X mutation	somatic	IDH1	mutation	R132:any:	no					BAY1436032	Active, not recruiting
NCT02762721	yes	FGFR2 fusions	somatic	FGFR2	fusion	any	no					observational only	Completed
NCT02762721	:duplicate:												
NCT03101839	yes	Part A: KRAS mut	somatic	KRAS	mutation,insertion,deletion	any	no					AZD4785	Completed
NCT03497624	yes	ROS1 fusion	somatic	ROS1	fusion	any	 no					biospecimen collection	Completed
NCT03497624	:duplicate:												
NCT03497624	:duplicate:												
NCT03964233	:skip:	(Phase 1a) MDM2 amp + TP53 WT in solid tumors;  (phase 1b, cohort 2)  MDM2 amp + TP53 WT	somatic	TP53	none		no	MDM2	amplification (should be yes but we do not have amp yet)			BI 907828, BI 754091 (Ezabenlimab), BI 754111	Recruiting
NCT03964233	:skip:	TP53 wt	somatic	TP53	none							BI 907828, BI 754091 (Ezabenlimab), BI 754111	Recruiting
NCT03964233	:skip:	TP53 point mutation (hence, TP53 muts themselves aren't being targeted per se -> :skip:)	somatic	TP53	mutation	any						BI 907828, BI 754091 (Ezabenlimab), BI 754111	Recruiting
NCT04083976	yes	FGFR mut or fusion	somatic	FGFR1,FGFR2,FGFR3,FGFR4	mutation,insertion,deletion,fusion	any					yes (e.g., FGFR gatekeeper & resistance mut)	Erdafitinib	Recruiting
NCT04083976	:duplicate:												
NCT04083976	:duplicate:												
NCT04083976	:duplicate:												
NCT04087876	yes	FGFR genomic alterations	somatic	FGFR1,FGFR2,FGFR3,FGFR4	mutation,insertion,deletion,fusion	any						Derazantinib	Available
NCT04100694	yes	NRG1 fusion	somatic	NRG1	fusion	any						MCLA-128	Available
NCT04100694	:duplicate:												
NCT04145297	yes	MAPK-mutated GI malignancies: KRAS, NRAS, HRAS,   BRAFnon-V600, MEK, and ERK	somatic	KRAS,NRAS,HRAS,ERK,ERK1,ERK2,ERK3,ERK5,ERK6,ERK7,ERK8,JNKK1,MAP2K1,MAP2K2,MAP2K3,MAP2K4,MAP2K5,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K12,MAP3K13,MAP3K2,MAP3K3,MAP3K4,MAP3K5,MAP3K6,MAP3K7,MAP3K8,MAP3K9,MAP4K3,MAPK1,MAPK10,MAPK11,MAPK12,MAPK13,MAPK14,MAPK15,MAPK2,MAPK3,MAPK4,MAPK6,MAPK7,MAPK8,MAPK9,MAPKAP1,MAPKAP3,MAPKAPK2,MAPKAPK3,MAPKAPK5,MAPKK1,MAPKK3,MAPKK5,MAPKK6,MAPKKK1,MAPKKK3,MAPKKK4,MAPKKK5,MAPKKK6,MAPKKKK3,MAPKSP1AP,MEK1,MEK2,MEK3,MEK4,MEK5,MEK6,MEKK,MEKK10,MEKK11,MEKK12,MEKK13,MEKK2B,MEKK6,MEKK7,MEKK8,MEKK9	mutation,insertion,deletion,fusion	any						Ulixertinib + Hydroxychloroquine	Recruiting
NCT04145297	yes	subjects may have BRAF non-V600	somatic	BRAF	mutation	any						Ulixertinib + Hydroxychloroquine	Recruiting
NCT04145297	yes	subjects may have BRAF non-V600	somatic	BRAF	mutation	V600:any::disqualifying:						Ulixertinib + Hydroxychloroquine	Recruiting
NCT04507503	yes	FGFR2 rearrangements	somatic	FGFR2	insertion,deletion,fusion	any						Futibatinib (TAS-120)	Available
NCT04507503	:duplicate:												
NCT04507503	:duplicate:												
NCT04566393	yes	MAPK pathway-altered solid tumor(s), including but not limited to              KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations	somatic	KRAS,NRAS,HRAS,ERK,ERK1,ERK2,ERK3,ERK5,ERK6,ERK7,ERK8,JNKK1,MAP2K1,MAP2K2,MAP2K3,MAP2K4,MAP2K5,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K12,MAP3K13,MAP3K2,MAP3K3,MAP3K4,MAP3K5,MAP3K6,MAP3K7,MAP3K8,MAP3K9,MAP4K3,MAPK1,MAPK10,MAPK11,MAPK12,MAPK13,MAPK14,MAPK15,MAPK2,MAPK3,MAPK4,MAPK6,MAPK7,MAPK8,MAPK9,MAPKAP1,MAPKAP3,MAPKAPK2,MAPKAPK3,MAPKAPK5,MAPKK1,MAPKK3,MAPKK5,MAPKK6,MAPKKK1,MAPKKK3,MAPKKK4,MAPKKK5,MAPKKK6,MAPKKKK3,MAPKSP1AP,MEK1,MEK2,MEK3,MEK4,MEK5,MEK6,MEKK,MEKK10,MEKK11,MEKK12,MEKK13,MEKK2B,MEKK6,MEKK7,MEKK8,MEKK9,BRAF	mutation,insertion,deletion,fusion	any						Ulixertinib	Available
NCT04566393	:duplicate:												
NCT04792463	yes	known or suggestive of hereditary BAP1 [germline]. Pathogenic, likely path. Variants in BAP1 incl those of uncertain signif.  Germline inactivation of BAP1	germline	BAP1	mutation,insertion,deletion,fusion	any						observational, prospective	Recruiting
NCT04792463	:duplicate:												
NCT04792463	:duplicate:												
NCT04792463	:duplicate:												
NCT04906473	yes	IDH1 mut	somatic	IDH1	mutation,insertion,deletion,fusion	any	no					KY100001	Not yet recruiting
NCT04962867	yes	selected FGFR genetic alterations (incl. fusion, mut, amp).  Other activating point muations allowed (not specified)); or FGFR1/2 amp. Study lists specific alterations!	somatic	FGFR1,FGFR2,FGFR3	fusion	any						E7090	Recruiting
NCT04962867	yes	activating mut	somatic	FGFR1	mutation	P150S, T340M, R445W, N546K, K656E						E7090	Recruiting
NCT04962867	yes	activating mut	somatic	FGFR2	mutation	C62Y, A67V, N82K, D101Y, E160K, E163K, M186T, R203H, R210Q, Q212K, R251Q,             S252W, P253R, P253L, A264T, W290C, K310R, Y328N, G364E, Y375C, C382R, A389T, V392A,         R399Q, H416R, I422V, H544Q, N549H, N549K, N549D, N549S, L560F, K659E, K659N, R664W,E718K, S791T						E7090	Recruiting
NCT04962867	yes	activating mut	somatic	FGFR3	mutation	G380E, G380R, A391E, K650T, K650E, K650Q, K650N						E7090	Recruiting
NCT04962867	yes	from exclusion criteria	somatic	FGFR1	mutation	V561:any::disqualifying:							
NCT04962867	yes	from exclusion criteria	somatic	FGFR2	mutation	V564:any::disqualifying:, V565:any::disqualifying:							
NCT04962867	yes	from exclusion criteria	somatic	FGFR3	mutation	V555:any::disqualifying:, V557:any::disqualifying:							
NCT04962867	yes	from exclusion criteria	somatic	FGFR4	mutation	V550:any::disqualifying:							
NCT04962867	:skip:	FGFR1,2 amp	somatic	FGFR1,FGFR2	amp							E7090	Recruiting
NCT04962867	yes	disqualifying:  genetic muts (excluding VUS): KRAS, NRAS, EGFR, BRAF V600,  or translocations  ALK, ROS1, or NTRK  (assume NTRK1,NTRK2,NTRK3).  We aren't checking translocations just yet here	somatic	BRAF	mutation	V600:any::disqualifying:							
NCT04962867	yes	disqualifying:  genetic muts (excluding VUS): KRAS, NRAS, EGFR, BRAF V600,  or translocations  ALK, ROS1, or NTRK  (assume NTRK1,NTRK2,NTRK3).  We aren't checking translocations just yet here	somatic	ALK,ROS1,NTRK1,NTRK2,NTRK3	fusion	any:disqualifying:							
NCT04973163	yes		somatic	KRAS	mutation	G12C						BI 1823911, with or without BI 1701963	Recruiting
NCT04973163	:duplicate:												
NCT05023655	yes 	ARID1A mutation	somatic	ARID1A	mutation,insertion,deletion,fusion	any						Tazemetostat	Recruiting
NCT05023655	:duplicate:												
NCT05023655	:duplicate:												
NCT05176665	yes	EGFR/cMET gene alterations or protein over expression:  cMET amp (CN>=5); or cMET overexpr; or EGFR overexpr; or other EGFR or cMET alteration where point mutation activates EGFR or cMET or indels, CN amp	somatic	EGFR,MET	mutation,insertion,deletion	any						EMB-01	Recruiting
NCT05176665	:duplicate:												
NCT05222971	yes	          -  Somatic or germline mutation of at least one the DNA damage repair gene including ATM,             ATR, BAP1, BARD1, BLM, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2, GEN1, FANCA, FANCD2, POLE,             MLH1, MSH2, MSH6, MRE11A, NBN, PALB2, PMS2, RAD50, RAD51, RAD51C, RAD51D, XRCC2             	somatic	:dna_repair:	mutation,insertion,deletion,fusion	any						Olaparib + durvalumab	Recruiting
NCT05222971	yes		germline	:dna_repair:	mutation,insertion,deletion,fusion	any						Olaparib + durvalumab	Recruiting
NCT05222971	:duplicate:												
NCT05228015	yes	NF2 deficiency (cohort 2)	somatic	NF2	mutation,insertion,deletion,fusion	any						IK-930	Recruiting
NCT05228015	yes	YAP1 or TAZ fusion (TAZ = WWTR1) (cohort 4)	somatic	YAP1,TAZ,WWTR1	fusion	any						IK-930	Recruiting
NCT05244551	yes	for CHOL: FGFR2 fusions and/or [re]arrangments	somatic	FGFR2	insertion,deletion,fusion	any						ABSK061	Recruiting
NCT05266300	yes	Pts who are DPYD-gene compound heterozyg not recommends for treatement. Eligible variants:  rs3918290(c.1905+1G>A)[splice donor] 	somatic	DPYD	mutation	1:97450057:97450057:C:T,1:97450057:97450057:G:A						5-FU, capecitabine, tegafur	Recruiting
NCT05266300	yes	rs67376798(c.2846A>T) 	somatic	DPYD	mutation	1:97082390:97082390:T:A,1:97082390:97082390:A:T						5-FU, capecitabine, tegafur	Recruiting
NCT05266300	yes	rs55886062(c.1679T>G) 	somatic	DPYD	mutation	1:97515786:97515786:A:C,1:97515786:97515786:T:G						5-FU, capecitabine, tegafur	Recruiting
NCT05266300	yes	rs56038477 (rs75017182)/(c.1236G>A)	somatic	DPYD	mutation	1:97573862:97573862:C:T,1:97573862:97573862:G:A						5-FU, capecitabine, tegafur	Recruiting
NCT05266300	yes		germline	DPYD	mutation	1:97450057:97450057:C:T,1:97450057:97450057:G:A						5-FU, capecitabine, tegafur	Recruiting
NCT05266300	yes		germline	DPYD	mutation	1:97082390:97082390:T:A,1:97082390:97082390:A:T						5-FU, capecitabine, tegafur	Recruiting
NCT05266300	yes		germline	DPYD	mutation	1:97515786:97515786:A:C,1:97515786:97515786:T:G						5-FU, capecitabine, tegafur	Recruiting
NCT05266300	yes		germline	DPYD	mutation	1:97573862:97573862:C:T,1:97573862:97573862:G:A						5-FU, capecitabine, tegafur	Recruiting
NCT05266300	:duplicate:												
NCT05275478	yes	have an MTAP deletion (homozygous)	somatic	MTAP	deletion	any						TNG908	Recruiting
NCT05275478	:duplicate:												
NCT05275478	:duplicate:												
NCT00397384	yes	general GI, not specificially CHOL or biliary, but mesh term is a hit.  KRAS WT sufficient, but concern seems to be p.12 & p.13 WTs	somatic	KRAS	mutation	G12:any::disqualifying:,G13:any::disqualifying:						cetuximab + erlotinib	Completed
NCT00654160	yes	general GI, not specifically CHOL/biliary, but mesh term is a hit. TA indel geotype. [ PMID: 25887876 indicates this is a poly-mutation, most commonly  as [A(TA)7TAA]  ]	somatic	UGT1A1	insertion	TA,TATA,TATATA,TATATATA,TATATATATA,TATATATATATA,TATATATATATATA						irinotecan + fluorouracil + leucovorin	Completed
NCT00654160	:duplicate:												
NCT05514912	yes	FGFR2 fusion/translocation pos or neg	somatic	FGFR2	fusion	any						infigratinib + nab-paclitaxel, cisplatin, gemcitabine	Not yet recruiting
NCT05514912	yes		somatic	FGFR2	fusion	none						nab-paclitaxel, cisplatin, gemcitabine	Not yet recruiting
NCT05514912	:duplicate:												
NCT05514912	:duplicate:												
NCT05510427	yes	FGFR2 fusion somatic	somatic	FGFR2	fusion	any						infigratinib + bevacizumab + atezolizumab	Not yet recruiting
NCT05510427	:duplicate:												
NCT05501912	yes		somatic	BRAF	mutation	V600:any:						ABM-1310	Not yet recruiting
NCT05501912	:duplicate:												
NCT05094336	yes	homozygous loss of CDKN2A and/or MTAP, or lost MTAP expression in tumor	somatic	CDKN2A,MTAP	deletion	any						AMG-193, with or without docetaxel	Recruiting
NCT05039892	yes	FGFR2 Gene Alterations, per title	somatic	FGFR2	mutation,insertion,deletion,fusion	any						3D185	Not yet recruiting
NCT05039892	:duplicate:												
NCT05429697	yes	PD-L1 expression 1% or more;  or MSI-H, or dMMR positive (loss of MLH1, MSH2, MSH6 or PMS2)	somatic	:mm_repair:	mutation,insertion,deletion,fusion	any						 Pembrolizumab + allogenic  NK cells (SMT-NK)	Recruiting
NCT05429697	:duplicate:												
